Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

Prostate

Volumn 42, Issue 1, 2000, Pages 26-33

  Strohmeyer, Dagmar ^a   Rössing, Christian ^b   Strauss, Franz ^b   Bauerfeind, Anja ^c   Kaufmann, Olaf ^b   Loening, Stefan ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Technische Fachhochschule ^*  (Germany)

Author keywords

Angiogenesis; Microvessel density; Progression; Prostate carcinoma

Indexed keywords

BLOOD CLOTTING FACTOR 8; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; TUMOR VASCULARIZATION;

BLOOD VESSELS; DISEASE PROGRESSION; HUMANS; MALE; MICROCIRCULATION; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; POSTOPERATIVE PERIOD; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 17544397076     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000101)42:1<26::AID-PROS4>3.0.CO;2-6     Document Type: Article

References (51)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
4. Folkman J. Clinical applications of angiogenesis research. N Engl J Med 1995;333:1757-1763.
5. Gimbrone MA, Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972;136:261-276.
6. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991;51:6180-6184.
7. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362:841-844.
8. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukocyte Biol 1994; 56:423-435.
9. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
10. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-831.
11. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992;7:261-266.
12. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
13. Weidner N. Angiogenesis in cancer. Invited commentary article. Am J Pathol 1995;147:9-19.
14. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder. Am J Pathol 1993;143:1255-1262.
15. Chopin DK, Caruelle JP, Colombel M, Palcy S, Ravery V, Caruelle D, Abbou CC, Barritault D. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993;150:1126-1130.
16. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994;74: 762-766.
17. Jaeger TM, Weidner N, Chew K, Moore DH, Kershman RL, Waldman FM, Carroll PR. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1994; 154:69-71.
18. Nguyen N, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1994;85:241-242.
19. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinoma of the gastrointestinal tract. Cancer Res 1993;53:4727-4735.
20. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Conolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
21. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
22. Boocock CA, Charnock Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK. Expression of vascular endothelial growth factor and its receptor fit and KDR in ovarian cancer. J Natl Cancer Inst 1995;87:506-516.
23. Reynolds K, Farazaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam A, Harris AL, Bicknell R. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994;86:1234-1238.
24. Fujimoto K, Ichimori Y, Kakizoe T. Increased serum levels of basic fibroblast growth factor in patients with renal cell cancer. Biochem Biophys Res Commun 1991;180:386-392.
25. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-4237.
26. Maxwell M, Naber SP, Wolfe HJ, Hedley-Whyte ET, Galanopoulos T, Neville-Golden J, Antoniades HN. Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res 1991;51:1345-1351.
27. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediatethickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 1988; 133:419-423.
28. Brawer MK. Quantitative microvessel density. A staging and prognostic marker in human prostatic carcinoma. Cancer 1996; 78:345-349.
29. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-687.
30. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
31. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75:2545-2551.
32. Wakui S, Furusato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S, Ushigome S. Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 1992;168:257-262.
33. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
34. Bettencourt MC, Bauer JJ, Sesterhenn A, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-465.
35. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5 to 7 adenocarcinoma. Cancer 1997;79:772-779.
36. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology 1999;53:542-547.
37. Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG. Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis. Urology 1998;51:79-85.
38. Schroeder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TMN classification of prostate cancer. Prostate [Suppl] 1992;4:129-138.
39. Pinkus GS, Etheridge CL, O'Connor EM. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffinembedded neoplasms using monoclonal and polyclonal antibodies. Am J Clin Pathol 1986;85:269-277.
40. Snedecor GW, Chochran WG. Statistical methods, 7th ed. Ames, IA: Iowa State University Press; 1980.
41. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993;24:220-226.
42. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994;44:869-875.
43. Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason score, microvessel density, and epithelial cell proliferation. Lab Invest 1995;73:844-850.
44. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304-2311.
45. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
46. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-6628.
47. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Olson BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
48. Catalona JC, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998;160:2428-2434.
49. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino PT, Humphrey PA, Hudson MLA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE, Miles B. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996;48: 47-57.
50. Yörükoglu K, Sagol Ö, Özkara E, Mungan U. Comparison of microvascularization in diagnostic needle biopsies and radical prostatectomies in prostate carcinoma. Eur Urol 1999;35:109-112.
51. Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H. Microvessel density in core biopsies of prostatic adenocarci-noma: a stage predictor? J Pathol 1997;182:205-210.